Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial.
Pracoń R, Spertus JA, Broderick S, Bangalore S, Rockhold FW, Ruzyllo W, Demchenko E, Nageh T, Grossman GB, Mavromatis K, Manjunath CN, Smanio PEP, Stone GW, Mancini GBJ, Boden WE, Newman JD, Reynolds HR, Hochman JS, Maron DJ; ISCHEMIA Research Group. Pracoń R, et al. Circ Cardiovasc Interv. 2024 Apr 17:e013435. doi: 10.1161/CIRCINTERVENTIONS.123.013435. Online ahead of print. Circ Cardiovasc Interv. 2024. PMID: 38629312
Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials.
Cordero A, Fernandez Olmo R, Santos-Gallego CG, Fácila L, Bonanad C, Castellano JM, Rodriguez-Mañero M, Seijas-Amigo J, González-Juanatey JR, Badimon JJ. Cordero A, et al. Among authors: seijas amigo j. Am J Cardiol. 2023 Oct 15;205:321-324. doi: 10.1016/j.amjcard.2023.07.145. Epub 2023 Aug 25. Am J Cardiol. 2023. PMID: 37633067
Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World-MEMOGAL Study.
Seijas-Amigo J, Mauriz-Montero MJ, Suarez-Artime P, Gayoso-Rey M, Estany-Gestal A, Casas-Martínez A, González-Freire L, Rodriguez-Vazquez A, Pérez-Rodriguez N, Villaverde-Piñeiro L, Castro-Rubinos C, Espino-Faisán E, Rodríguez-Mañero M, Cordero A, González-Juanatey JR; Investigadores MEMOGAL. Seijas-Amigo J, et al. Am J Cardiovasc Drugs. 2023 Sep;23(5):583-593. doi: 10.1007/s40256-023-00604-6. Epub 2023 Aug 23. Am J Cardiovasc Drugs. 2023. PMID: 37612529 Free PMC article.
Effect of dapagliflozin on COVID-19 infection and risk of hospitalization.
Salgado-Barreira A, Seijas-Amigo J, Rodriguez-Mañero M, Piñeiro-Lamas M, Eiras S, Cordero A, Gonzalez-Juanatey JR, Figueiras A. Salgado-Barreira A, et al. Among authors: seijas amigo j. J Antimicrob Chemother. 2023 Sep 5;78(9):2335-2342. doi: 10.1093/jac/dkad241. J Antimicrob Chemother. 2023. PMID: 37549309 Free PMC article.
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.
Seijas-Amigo J, Salgado-Barreira Á, Castelo-Dominguez R, Pérez-Álvarez MT, Ponce-Piñón B, Fernández-Silva M, Rodríguez-Barreiro M, Pereira-Pía M, Iglesias-Moreno JM, Gago-García M, Montáns-García R, Fernandez-Perez A, FragaGayoso D, Fernandez-Montenegro M, Riveiro-Barciela B, Rilla-Villar N, Cordero A, RodríguezMañero M, González-Juanatey JR. Seijas-Amigo J, et al. Prim Care Diabetes. 2023 Aug;17(4):366-372. doi: 10.1016/j.pcd.2023.05.004. Epub 2023 May 23. Prim Care Diabetes. 2023. PMID: 37230813 Free article.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis.
Seijas-Amigo J, Cordero A, Olmo RF, Cortez Quiroga GA, Fácila L, Salgado-Barreira Á, Reyes-Santías F, Romero-Menor C, Murillo JR, Rodríguez-Mañero M, Bello Mora MC, Valle A, Sandin M, Pamias RF, Bañeras J, García PB, Lorenzo MC, Sánchez-Alvarez S, López-Rodríguez L, González-Juanatey JR. Seijas-Amigo J, et al. J Cardiovasc Pharmacol. 2023 Jan 1;81(1):70-75. doi: 10.1097/FJC.0000000000001365. J Cardiovasc Pharmacol. 2023. PMID: 36219195
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry.
Cordero A, Fernández Olmo MR, Cortez Quiroga GA, Romero-Menor C, Fácila L, Seijas-Amigo J, Rondán Murillo J, Sandin M, Rodríguez-Mañero M, Bello Mora MC, Valle A, Fornovi A, Freixa Pamias R, Bañeras J, Blanch García P, Clemente Lorenzo MM, Sánchez-Álvarez S, López-Rodríguez L, González-Juanatey JR. Cordero A, et al. Among authors: seijas amigo j. Eur J Clin Invest. 2022 Dec;52(12):e13863. doi: 10.1111/eci.13863. Epub 2022 Sep 5. Eur J Clin Invest. 2022. PMID: 36039486
Polypill Strategy in Secondary Cardiovascular Prevention.
Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, Sanchez PL, Marin Ortuño F, Vazquez Rodriguez JM, Domingo-Fernández A, Lozano I, Roncaglioni MC, Baviera M, Foresta A, Ojeda-Fernandez L, Colivicchi F, Di Fusco SA, Doehner W, Meyer A, Schiele F, Ecarnot F, Linhart A, Lubanda JC, Barczi G, Merkely B, Ponikowski P, Kasprzak M, Fernandez Alvira JM, Andres V, Bueno H, Collier T, Van de Werf F, Perel P, Rodriguez-Manero M, Alonso Garcia A, Proietti M, Schoos MM, Simon T, Fernandez Ferro J, Lopez N, Beghi E, Bejot Y, Vivas D, Cordero A, Ibañez B, Fuster V; SECURE Investigators. Castellano JM, et al. N Engl J Med. 2022 Sep 15;387(11):967-977. doi: 10.1056/NEJMoa2208275. Epub 2022 Aug 26. N Engl J Med. 2022. PMID: 36018037 Clinical Trial.
21 results